Navigation Links
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
Date:3/11/2009

Net Revenues: EPIAO 121,220 16,618 -- 121,220 16,618 TPIAO 43,074 5,905 -- 43,074 5,905 Intefen 4,123 565 -- 4,123 565 Inleusin 1,027 141 -- 1,027 141 Iron 3,206 440 -- 3,206 440 Export 6,784 930 -- 6,784 930 Others 739 101 -- 739 101 Total revenues 180,173 24,700 180,173 24,700 Cost of revenues (17,427) (2,389) -- (17,427) (2,389) Gross profit 162,746 22,311 162,746 22,311 Operating expenses Research and development costs (11,635) (1,595) -- (11,635) (1,595) Sales, marketing and distribution expenses (84,187) (11,541) -- (84,187) (11,541) General and administrative expenses (18,379) (2,520) 995 (1) (17,384) (2,383) Total operating expenses (114,201) (15,656) (113,206) (15,519) Operating income 48,545 6,655 49,540 6,792 Other income/ (expenses), net Interest income 36,015 4,937 36,015 4,937 Interest expense (825) (113) -- (825) (113) Grant income 1,067 146 -- 1,067 146 Others 205 28 -- 205 28 Total other income, net 36,462 4,998 36,462 4,998 Income before income tax expense and minority
'/>"/>
SOURCE 3SBio Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
2. 3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009
3. 3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
4. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
5. 3SBio Inc. Announces Third Quarter 2008 Results
6. 3SBio Inc. Files for SFDA Approval of NuLeusin
7. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
8. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
9. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
10. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
11. 3SBio Inc. Announces Results of Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):UCLA researchers engineer bacteria to turn carbon dioxide into liquid fuel 2University of California, San Francisco, researcher receives ASBMB-Merck Award 2CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 1CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 2CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 3CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 4CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 5CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 6CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 7CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 8CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 9CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 10CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 11CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 12CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 13CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 14CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 15Global Spinal Nonfusion Market to Reach Almost 242 Billion By 2013 According to Millennium Research Group 5822 1Global Spinal Nonfusion Market to Reach Almost 242 Billion By 2013 According to Millennium Research Group 5822 2Global Spinal Nonfusion Market to Reach Almost 242 Billion By 2013 According to Millennium Research Group 5822 3Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 1Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 2Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 3Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 4Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 5Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 6Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 7Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 8Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 9Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 10Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 11Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 12Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 13Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 14Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 15